Xenetic 股价、新闻与催化剂

股票表现

股价为何变动

最新公司动态“Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics”发布后，XBIO 于 2026年9月16日 收于 $2.19，较前一交易日下跌 48.7%。该变动发生在与这则公司动态对应的交易时段。

公司概览

未来催化剂

近期新闻

1. 01
   2026-09-16 11:00 EST

   Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

2. 02
   2026-08-07 12:35 EST

   Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

3. 03
   2026-06-04 12:40 EST

   Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

4. 04
   2026-06-01 13:02 EST

   Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

5. 05
   2026-05-13 12:05 EST

   Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

相似股票

商业成熟度、治疗领域或催化剂模式相近的同行公司。